Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Seattle Genetics, Takeda & Millennium begin phase-III Aethera trial of brentuximab vedotin for post-transplant Hodgkin lymphoma
Seattle Genetics, Takeda & Millennium begin phase-III Aethera trial of brentuximab vedotin for post-transplant Hodgkin lymphoma
Seattle Genetics, Takeda & Millennium begin phase-III Aethera trial of brentuximab vedotin for post-transplant Hodgkin lymphoma
Submitted by
admin
on April 10, 2010 - 12:45pm
Source:
Pharmabiz
News Tags:
Seattle Genetics
Takeda
brentuximab vedotin
Hodgkin's lymphoma
Headline:
Seattle Genetics, Takeda & Millennium begin phase-III Aethera trial of brentuximab vedotin for post-transplant Hodgkin lymphoma
Do Not Allow Advertisers to Use My Personal information
